ReviewAmerican journal of clinical dermatology2020
Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments.
Review in American journal of clinical dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 130 citations in OpenAlex.
- Efficacy and safety of Janus kinase and TYK2 inhibitors in the treatment of generalized pustular psoriasis and palmoplantar pustulosis: a systematic review.Immunologic research · 2026Pooled it
- Smoking, alcohol consumption, and psoriasis risk: a systematic review and dose-response meta-analysis of observational studies.Frontiers in public health · 2026Pooled it
- Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68-week randomized Phase 3 trial.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.American journal of clinical dermatology · 2023Trial
- Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.The Journal of dermatology · 2021Trial
- Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature.Health science reports · 2026Review
- Palmoplantar pustulosis: pathogenesis, differential diagnosis, and treatment.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Review
- A Patient with Pustulotic Arthro-osteitis with Isolated Spinal Lesions Successfully Treated with Risankizumab.Internal medicine (Tokyo, Japan) · 2026Article
- Evaluation of Diabetes Mellitus, Hyperlipidemia, and Thyroid Disease Comorbidities in Palmoplantar Pustulosis.The Eurasian journal of medicine · 2026Article
- COVID-19 Infection vs Vaccination and the Risk of New-onset Psoriasis.Acta dermato-venereologica · 2026Article
- Deucravacitinib in dermatology: current indication and existing off-label data.Drugs in context · 2026Review
- Psoriasis as a spatial immune ecosystem: insights from single-cell and spatial transcriptomics.Frontiers in immunology · 2026Review
- Case Report: Abrocitinib treatment for refractory palmoplantar pustulosis.Frontiers in medicine · 2026Article
- IL-4Rα antagonist (Stapokibart) in refractory palmoplantar pustulosis: a case report and literature review of Th2-targeted therapies.Frontiers in immunology · 2026Review
- Targeting the JAK/STAT pathway in palmoplantar pustulosis: a review.Annals of medicine · 2025Review
- Efficacy and Safety of Tofacitinib in Palmoplantar Pustulosis: A Retrospective Study.Acta dermato-venereologica · 2025Article
- Effectiveness and Safety of Delgocitinib Cream in Pustulosis Palmoplantaris: A Case Series.Acta dermato-venereologica · 2025Article
- Review of Promising Off-Label Use of Deucravacitinib.International journal of molecular sciences · 2025Review
- Th17 cells with regulatory phenotype are the main IL-17F and IL-26 producers in palmoplantar pustulosis.JCI insight · 2025Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Palmoplantar pustulosis (PPP) is a chronic, recurrent skin disease belonging to the spectrum of psoriasis. It is characterized by an eruption of sterile pustules on the palms and soles. Recent studies in PPP have focused on genetic differences between pustular phenotypes and the role of the innate immunological system and the microbiome in the etiopathogenesis of the disease. Mutations in IL36RN (a major predisposing factor for generalized pustular psoriasis) were found in selected patients with PPP and were associated with earlier disease onset. Studies have shown that the interleukin (IL)-17 and IL-36 pathways might be involved in the pathogenesis of PPP. A microbiome has been demonstrated in the vesicopustules of PPP, and an abundance of Staphylococcus appears to be increased by smoking. Improved understanding of the underlying etiopathogenesis of PPP has led to advances in treatment options, and targeted therapies for PPP have been evaluated or are under evaluation against more than 12 molecules in ongoing clinical trials. These targets include CXCR2 (IL-8 receptor type B), granulocyte colony-stimulating factor receptor, IL-1 receptor, IL-8, IL-12, IL-23, IL-17A, IL-17 receptor, IL-36 receptor, phosphodiesterase-4, and tumor necrosis factor-α.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.